These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17075387)

  • 21. HIV vaccine efficacy trials: A brief history, and options for going forward.
    McKinnon LR; Card CM;
    AIDS Rev; 2010; 12(4):209-17. PubMed ID: 21179185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
    Huang Y; DiazGranados C; Janes H; Huang Y; deCamp AC; Metch B; Grant S; Sanchez B; Phogat S; Koutsoukos M; Kanesa-Thasan N; Bourguignon P; Collard A; Buchbinder S; Tomaras GD; McElrath J; Gray G; Kublin JG; Corey L; Gilbert PB
    Curr Opin Virol; 2016 Apr; 17():57-65. PubMed ID: 26827165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
    Longini IM; Datta S; Halloran ME
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.
    Graziani GM; Angel JB
    J Int AIDS Soc; 2015; 18(1):20497. PubMed ID: 26561337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine nanoparticles for protection against HIV infection.
    Aikins ME; Bazzill J; Moon JJ
    Nanomedicine (Lond); 2017 Mar; 12(6):673-682. PubMed ID: 28244816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
    Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
    J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Some statistical issues in HIV vaccine trials.
    Rida WN; Lawrence DN
    Stat Med; 1994 Oct 15-30; 13(19-20):2155-77. PubMed ID: 7846417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.
    Excler JL; Parks CL; Ackland J; Rees H; Gust ID; Koff WC
    Biologicals; 2010 Jul; 38(4):511-21. PubMed ID: 20537552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.
    Cafaro A; Tripiciano A; Sgadari C; Bellino S; Picconi O; Longo O; Francavilla V; Buttò S; Titti F; Monini P; Ensoli F; Ensoli B
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S13-29. PubMed ID: 26096836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approaches to preventative and therapeutic HIV vaccines.
    Gray GE; Laher F; Lazarus E; Ensoli B; Corey L
    Curr Opin Virol; 2016 Apr; 17():104-109. PubMed ID: 26985884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the development of HIV-1 Tat-based vaccines.
    Caputo A; Gavioli R; Ensoli B
    Curr HIV Res; 2004 Oct; 2(4):357-76. PubMed ID: 15544457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand: implications for vaccine trials.
    Buchacz K; Hu DJ; Vanichseni S; Mock PA; Chaowanachan T; Srisuwanvilai LO; Gvetadze R; Van Griensven F; Tappero JW; Kitayaporn D; Kaewkungwal J; Choopanya K; Mastro TD
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):853-60. PubMed ID: 15213570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
    Singh A; Boggiano C; Eller MA; Maciel M; Marovich MA; Mehra VL; Mo AX; Singleton KL; Leitner WW
    Vaccine; 2023 Jul; 41(31):4439-4446. PubMed ID: 37331838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges in the development of an HIV-1 vaccine.
    Barouch DH
    Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical development of candidate HIV vaccines: different problems for different vaccines.
    Shapiro SZ
    AIDS Res Hum Retroviruses; 2014 Apr; 30(4):325-9. PubMed ID: 24168166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the effect of HIV vaccination on infectiousness.
    Rida WN
    Stat Med; 1996 Nov 15-30; 15(21-22):2393-404; discussion 2405-12. PubMed ID: 8931209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 40. Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.
    Huang Y; Gilbert PB; Fu R; Janes H
    Biostatistics; 2017 Apr; 18(2):230-243. PubMed ID: 27649715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.